Burning Rock Biotech Limited (BNR) Stock Overview
Explore Burning Rock Biotech Limited’s financial performance, market position, analyst ratings, and future outlook.
Burning Rock Biotech Limited (BNR)
Key Financials
Key Financials
Market Cap
11.2M
P/E Ratio
-1.16
EPS (TTM)
$-0.82
ROE
-0.11%
BNR Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Burning Rock Biotech Limited (NASDAQ: BNR) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Burning Rock Biotech Limited's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of BNR on the NASDAQ shows an RSI of 58.99, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $17.48 for the NASDAQ listing.
Key metrics behind Burning Rock Biotech Limited's NASDAQ-traded stock include a P/E ratio of -1.16 and a market capitalization of 11.2M. Combined with our AI analysis, these give both institutional and retail investors a clear view of BNR on the NASDAQ.